VH298 is a cell-permeant inhibitor of von Hippel-Lindau disease tumor suppressor (VHL; Kd = 90 nM by isothermal titration calorimetry). VHL is a component of the complex that polyubiquitinates hydroxylated hypoxia-inducible factor-α (HIF-α) isoforms leading to proteasomal degradation. Through its effects on VHL, VH298 promotes the accumulation of HIF-α in a concentration- and time-dependent manner, resulting in the upregulation of HIF-target genes.
VH298 is a cell-permeant inhibitor of von Hippel-Lindau disease tumor suppressor (VHL; Kd = 90 nM by isothermal titration calorimetry). VHL is a component of the complex that polyubiquitinates hydroxylated hypoxia-inducible factor-α (HIF-α) isoforms leading to proteasomal degradation. Through its effects on VHL, VH298 promotes the accumulation of HIF-α in a concentration- and time-dependent manner, resulting in the upregulation of HIF-target genes.
Shipping & Handling
Shipped In
Room Temperature in continental US; may vary elsewhere
Safety & Storage
Storage Temperature
-20°C
Safety Statement
WARNING This product is not for human or veterinary use. Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Room Temperature in continental US; may vary elsewhere
Safety & Storage
Storage Temperature
-20°C
Safety Statement
WARNING This product is not for human or veterinary use. Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Regulatory & Compliance
We’re currently in BETA - Interested in joining? Let us know and we’ll get you set up with early access.
We’re currently in BETA - Interested in joining? Let us know and we’ll get you set up with early access.